Pharmaceutical Business Investment Opportunities in Hyderabad

The business specializes in providing pharmaceutical and orthopedic solutions directly to local healthcare professionals, including physicians, gynecologists, orthopedic specialists, and gastroenterologists. - The top products of the company are calcium supplements, and vitamin supplements among other tablets, capsules, and soft gels. - The products are manufactured by 3rd party and sold under our own brand. - The company serves approximately 100 clients generating yearly sales of INR 55 lakh. - A team of 3 employees specializing in marketing and sales promotes the company's goods. - Duly compliant private limited entity with necessary certifications and approval.

Medical and pharmaceuticals distribution company that supplies over-the-counter medicines, pharmaceutical products, and surgical items. - We have tied up with 80+ hospitals, wholesalers, and retailers. - Company is currently operational in two locations - Trivandrum and Kozhikode. We also have warehouses there. - We distribute 350+ products of the brand Cipla, Tynor, Polymed. - Our sales have increased due to an increase in clientele. - We are developing a B2B platform as well. - The valuation is based on the future growth projections of the company. - The price of the product ranges from INR 30-40 lakhs hence we are able to achieve the given revenue with 8 employees.

Medical and pharmaceuticals distribution company that supplies over-the-counter medicines, pharmaceutical products, and surgical items. - We have tied up with 80+ hospitals, wholesalers, and retailers. - Company is currently operational in two locations - Trivandrum and Kozhikode. We also have warehouses there. - We distribute 350+ products of the brand Cipla, Tynor, Polymed. - Our sales have increased due to an increase in clientele. - We are developing a B2B platform as well. - The valuation is based on the future growth projections of the company. - The price of the product ranges from INR 30-40 lakhs hence we are able to achieve the given revenue with 8 employees.

Company is in partnership with a pharma manufacturing company to sell 6 novelty pain management drugs across India. Have established our network with more than 9,000 doctors and growing. Our revenue was low for the first 8-9 months and now with our good relationship with doctors, we have been able to reach multiple hospitals and clinics. In last 3 months we have already crossed INR 1.5 crore of revenue. We project the same growth rate for the future and are seeking funds to increase our presence in other cities. Director of the company has 25 years of experience. We aim to reach break even in next 4-5 months. Company owned assets include computers, laptops and furniture.

We incorporated our startup both in Hyderabad, India five years back and in Foothill Ranch, California, USA one year ago. - Our co-founders are a team of 5 experienced PhDs and a medical doctor with clinical research experience in 3 multi-national pharma companies. We also have a woman co-founder (an Indian national) with an MMS degree. We have also hired an experienced auditor (in India) /CPA (in the USA) to help us in regulatory filings with respective government authorities. We also have an experienced business advisor (an Indian national). - Our co-founders have contributed >USD 108,000 so far. - Currently developing 3 new chemical entities (NCEs): Enhanced Naproxen (E-Naproxen), Enhanced irinotecan (E-Irinotecan), and Enhanced Aspirin (E-Aspirin) - Our initial focus is on the US market and we will bring our products to India and other major markets once we gain respectable sales figures in the US market. - Planning to develop these NCEs in the USA through the most economical (<USD 10 million) and shortest (<1.5–2.5 years) USFDA’s 505 (b) (2) regulatory route, which also grants 3-5 years exclusivity along with approval. - Currently, our NCEs are in the pre-clinical stage and will get all the regulatory approvals as per the requirement. - After securing the required funding (or equivalent amount in INR), we will take up the development of our first product. - Our startup was among the top 60 startups selected for acceleration under South Korea’s latest K-Startup Grand Challenge Program. Our CSO attended this acceleration program in Korea. - We have already obtained three patents (US, Canadian and Indian patents) on Enhanced Naproxen and Enhanced Aspirin and we will file provisional patent applications on Enhanced Irinotecan as soon as we secure the required seed funding.